TCMD — Tactile Systems Technology, Inc.

Tactile Medical (TCMD) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $85.8 million, up 17% year-over-year.
• Lymphedema Revenue: $72.4 million, an 11% increase year-over-year; 10% sequential growth from Q2.
• Airway Clearance Revenue: $13.4 million, a significant 71% increase year-over-year; 3% sequential growth.
• Gross Margin: Increased to 76%, up 80 basis points year-over-year.
• Adjusted EBITDA: Rose 34% year-over-year to $14.4 million.
• Net Income: Increased to $8.2 million, or $0.36 per diluted share, compared to $5.2 million, or $0.21 per diluted share in Q3 2024.
• Cash Position: Ended Q3 with $66 million in cash and no outstanding borrowings.

2. Strategic Updates and Business Highlights

• Sales Force Expansion: Increased total sales representatives to 329, exceeding the year-end goal of 300, with a focus on optimizing territory management.
• Product Innovation: Continued strong demand for Nimbl and the upcoming next-generation AffloVest, which is under FDA review.
• Clinical Evidence Generation: Presented new data on Flexitouch Plus at a major conference, supporting its effectiveness for head and neck cancer-related lymphedema.
• Operational Improvements: Implementation of AI technology in order operations to enhance efficiency and accuracy.
• Market Positioning: Strengthened relationships with top DMEs and improved product awareness, particularly for bronchiectasis treatment.

3. Forward Guidance and Outlook

• Revenue Guidance: Raised for full-year 2025 to a range of $317 million to $321 million, reflecting 8% to 10% growth year-over-year.
• Lymphedema Growth Expectation: Revised to 3% to 4% for Q4 2025, while airway clearance products are expected to grow 52% to 55%.
• Adjusted EBITDA Guidance: Increased to approximately $38 million to $39.5 million for 2025.

4. Bad News, Challenges, or Points of Concern

• Payer Mix Dynamics: Notable shifts in payer mix, with Medicare sales increasing 130% year-over-year, while commercial and VA channels declined by 9%.
• Market Headwinds: Previous documentation interpretation changes by Medicare created challenges that impacted growth; however, the company is adapting to new policies.
• Competitive Landscape: While TCMD is gaining market share, competition remains strong, particularly in the airway clearance segment.

5. Notable Q&A Insights

• AffloVest Performance: Continued strong growth attributed to deep DME relationships, product preference, and increased awareness of bronchiectasis.
• Lymphedema Market Growth: The market is growing at approximately 10%, and TCMD aims to match this growth with its strategic initiatives.
• NCD Impact: The transition to the NCD is expected to provide a more straightforward pathway for patients to access advanced pump therapy, although significant policy changes may take time.
• Sales Strategy: The company is satisfied with its current sales rep count but will adjust based on territory growth needs.

Overall, Tactile Medical demonstrated strong financial performance in Q3 2025, driven by strategic investments in sales and product innovation, while navigating challenges related to payer dynamics and competition. The outlook remains positive with raised revenue and EBITDA guidance for the year.